The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.
Who is eligible for a Covid-19 vaccine booster? The vaccine is the best way to protect yourself against serious illness and hospitalisation from Covid-19. That’s why people at higher risk, such as ...
Russia announces the development of an mRNA cancer vaccine, slated for a 2025 launch. Pre-clinical trials demonstrate tumor suppression and metastasis reduction. AI integration promises to ...
Russia has developed a cancer vaccine for patients. Representational Image/Pixabay Russia is all set to roll out a vaccine against cancer in the New Year. It will be available to patients for free ...
A Dec. 10 Instagram post (direct link, archive link) claims Robert F Kennedy Jr.'s comments on vaccines have been limited to advocating for more research. "RFK is saying one thing and one thing ...
Johnson & Johnson has received coal in its stocking from the FDA as manufacturing issues have tripped up the company’s attempt to gain approval of its subcutaneous version of lung cancer drug ...
Rates of invasive pneumococcal disease are at their highest levels since 2004. While more effective vaccines have been approved for use in Australia, most at-risk people can't get them ...
It is important to consolidate data on PCV10 and PCV13 impact on invasive pneumococcal disease (IPD) in all ages to determine persistent vaccine-type serotypes and the main replacement non-vaccine ...
“New generation vaccines need to be rolled out through the National Immunisation Program without further delay. We simply can’t risk not having the best available pneumococcal protection ...
The dangerous pneumococcal disease can be fatal to babies and children. Picture: CDC Pediatrician and infectious disease researcher Professor Peter Richmond said declining rates of vaccination ...